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Advances in biotechnology over the last ten years have made
it possible for the researcher to alter gene expression in vivo in
many diverse ways (1). With the establishment of embryonic
stem (ES)
 
1
 
 cell technology (2), more subtle and precise alter-
ations can now be achieved than were previously possible us-
ing microinjection techniques. However, to date germline
transmission has only been achieved with mouse ES cells, and
microinjection continues to be the method most widely used
for other species. While the mouse has a number of advan-
tages, not least the depth of our knowledge of its genetics,
other species are being increasingly used for transgenic studies
due to their greater suitability for addressing specific ques-
tions. We will briefly review the application of transgenic tech-
nology to nonmurine species as it stands at present, with par-
ticular emphasis on developments appertaining to biomedical
research.
 
Transgenesis by pronuclear injection
 
A number of significant limitations regarding the application
of pronuclear injection to nonmurine animals have been iden-
tified (3), not least being the time and cost. Such limitations
are due to longer gestation and generation times, reduced lit-
ter sizes, and higher maintenance costs. Further consideration
must be given to the large numbers of fertilized eggs (and
hence donor animals) required for microinjection, the high
cost of carrying nontransgenic offspring to term, and the rela-
tively low efficiency of gene integration. Such limitations are
particularly severe for the production of bovine transgenics
and, as a consequence, more significant departures from the
standard procedures used for the mouse have been adopted
for this species (4). For example, the use of in vitro embryo
production in combination with gene transfer technology has
played a large role in the development of transgenic cattle.
The development of microinjected embryos through to the
morula/blastocyst stage in recipient rabbits or sheep, enables
sexing, transgene screening, and cloning to take place before
reintroduction into the natural host, providing that such
screening methods are
 
 
 
robust and reliable.
The major problem regarding pronuclear microinjection is
that the exogenous DNA integrates randomly into chromo-
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somal DNA. Position effects, where the transgene is influ-
enced by its site of integration in the host chromosome (5), can
have major consequences on the expression of the transgene,
including loss of cell specificity, inappropriately high copy
number–independent expression and complete silencing of the
transgene. This is of greater concern in nonmurine transgene-
sis where the investment is higher. Position-independent, copy
number–related expression can be achieved using sequences
such as the locus control regions identified upstream of the
 
b
 
-globin gene cluster and downstream of the CD2 gene (6, 7),
the A elements which flank the chicken lysozyme gene (8), and
matrix attachment regions (9). Such elements have been
shown to function across species barriers, and their incorpora-
tion into gene constructs can overcome position effects and im-
prove expression of heterologous genes within specific cell
types (5). In many cases, simply including large amounts of
flanking sequences may be sufficient to overcome position ef-
fects and direct expression to specific tissues. To this end, the
development and use of P1 (10), bacterial artificial chromo-
some (BAC) (11) and yeast artificial chromosome (YAC) vec-
tors (12) for cloning of large segments of DNA, should greatly
improve the chances of including important regulatory ele-
ments, including those involved in chromatin structure, within
the transgene construct.
 
Embryonic stem cell technology
 
With the development of ES cell technology in the mouse (2),
genetic manipulations can be performed in cell culture using
appropriate selection strategies to permit the directed integra-
tion of the transgene to a specific region of the chromosome
via homologous recombination. With the advent of homolo-
gous recombination, the researcher is able to insertionally in-
activate, replace, or introduce subtle alterations to the endoge-
nous gene of interest. Once the intended genetic change has
been verified, the appropriate ES cells are introduced into
blastocysts by microinjection, and, during subsequent gesta-
tion, may contribute to the developing embryo. If such a con-
tribution is made, then by definition the resulting animal
would be chimeric, being derived in part from the ES cells
originating in culture. Assuming that the chimerism extends to
the germline, then an appropriate breeding strategy will lead
to the recovery of nonchimeric heterozygotes and, if viable,
mice which are homozygous for the genetic change.
Most attempts to isolate and culture inner cell mass (ICM)
cells from other species are based on the methods used for the
mouse. ES cells are maintained in culture in the presence of
mouse-derived differentiation-inhibiting agents, provided ei-
ther as a media supplement or through cocultivation in the
presence of feeder cells. It has been suggested that these
mouse-derived agents do not adequately prevent differentia-
tion of stem cells in species other than the mouse, and pluripo-
tent rat ES cells, capable of producing chimeras, were found to
grow best on primary rat embryonic fibroblasts as the feeder
layer (13). Freshly isolated cells from ICMs have been injected
into blastocysts to produce chimeric offspring in both sheep
and cattle (14), and their totipotency at this stage is further
demonstrated by their ability to produce offspring after trans-
fer into enucleated oocytes (15).
 
 
 
Such nuclear transfer tech-
niques are potentially very useful for the production of clonal
offspring and would avoid the initial chimeric generation ne-
cessitated by the injection of ES cells into blastocysts. Re-
cently, bovine-specific culture methods have shown promise
with cells of up to 27 d of age maintaining their ability to direct
normal calf development following nuclear transfer (16). How-
ever, at the present time the reliable generation of bovine ES
cell lines requires the pooling of ICMs from several blastocysts
and further efforts are required to enable the long-term cul-
ture of clonal bovine ES cells. Although to date chimeric ani-
mals have been generated from several species including the
pig (17), in no species other than the mouse has germline
transmission of an ES cell been successfully demonstrated.
This remains a major goal for the future and may well require
the use of novel strategies which depart widely from the tradi-
tional methods used in the mouse.
 
Nonmurine species in biomedical research
 
Selected physiological questions may be more conveniently
modelled in the rat or in larger species. Not only can physical
size be an advantage for biochemical sampling and physiologi-
cal analyses, but certain genes may provide useful information
when introduced into, for example, the rat genome when par-
allel experiments in the mouse would be ineffective. Examples
include the modulation of blood pressure by the mouse 
 
Ren-2
 
gene (18) and the modeling of inflammatory disease (19). In
both cases, but for different reasons, no phenotype was ob-
served in the respective transgenic mice, highlighting one of
the advantages of having alternative species for understanding
physiological mechanisms and the etiology of disease. More
recently, a number of transgenic experiments have been un-
dertaken to investigate lipoprotein metabolism. The human
apolipoprotein A-1 gene was successfully expressed in the rat
(20), resulting in increased serum HDL cholesterol concentra-
tions, and attempts to therapeutically lower apo B100, and
hence LDL and lipoprotein(a) concentrations, in the rabbit
were successful (21) but resulted in complications. Although
the targeted expression of the apo B–editing protein in the
liver of the transgenic rabbits resulted in reduced LDL and li-
poprotein(a) concentrations as intended, many of the animals
developed liver dysplasia, suggesting that high level expression
of the editing protein had unforeseen and detrimental side ef-
fects, possibly via the editing of other important mRNAs.
 
 
 
The
rabbit has also been used in HIV-1 research, with the develop-
ment of a line expressing the human CD4 protein on T lym-
phocytes (22). Susceptibility to HIV infection was demon-
strated, and although the rabbits are less sensitive to infection
than humans, they may represent an inexpensive alternative to
primates for many studies.
Gene transfer in farm animals was initially aimed towards
improving production efficiency, carcass quality (23), and dis-
ease resistance of livestock. However, it has been suggested
that the simple over-expression of hormones such as growth
hormone may have unacceptable side effects. Recently some
elegant studies of growth using transgenic rats have been per-
formed and are likely to yield valuable information on the bio-
chemistry and physiology of growth (24, 25). A more success-
ful application of transgenesis in farm animals has been the
production of biomedically important proteins. The two most
popular methods have been to direct expression to hematopoi-
etic cells or to the lactating mammary gland. In the former
case, transgenic swine expressing high levels of human hemo-
globin were generated using the locus control region from the
 
b
 
-globin gene cluster to overcome positional effects and direct
expression to the hematopoietic cells (26). However, due to its
natural ability to synthesize and secrete large amounts of pro-
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tein, the mammary gland has become the primary focus for the
expression of heterologous proteins in large mammals. Trans-
gene expression has been successfully directed to the mam-
mary gland using promoter sequences from milk protein genes
such as those encoding ovine 
 
b
 
-lactoglobulin (BLG), goat
 
b
 
-casein, and murine whey acidic protein. The BLG promoter
was used to direct expression of human 
 
a
 
1
 
-antitrypsin in lines
of transgenic mice and sheep (27). Interestingly, a wide varia-
tion in expression was observed between mouse lines, and
from one lactation to another within a single line. In sheep
however, similar high levels of heterologous protein were ex-
pressed in milk over consecutive lactations and over several
generations in a given transgenic line, allowing the viable de-
velopment of a flock of transgenic sheep. In separate studies
high levels of expression of human tissue plasminogen activa-
tor were obtained in goat’s milk under the control of the goat
 
b
 
-casein promoter (28). The development of suitable purifica-
tion methods and the use of transgenically produced proteins
in clinical trials are well advanced, and, if successful, will have
important implications for the production of human proteins
in transgenic livestock. Poor expression of the ovine promoter
in the mouse may reflect species differences in recognizing het-
erologous versus homologous promoters and raises questions
concerning the predictive value of mouse models. At best
therefore the generation of transgenic mice may, in certain
cases, only be a guide to the potential success of a transgene
construct in another species.
Gene transfer could equally be used to enhance the quality
and suitability of milk derived from domesticated animals as a
food for human consumption. Human milk is devoid of 
 
b
 
-lac-
toglobulin, which is responsible for most of the allergies to
cows’ milk, and has a relatively high content of lactoferrin,
which is important in iron transport and combating bacterial
infections. One could envisage in the future the reduction of
saturated fat content in cows’ milk and the knock-out of un-
wanted proteins or their replacement with other more useful
components. Through the manipulation of milk constituents it
should be possible to more closely emulate the desirable com-
ponents of human milk. The alteration of milk composition
would appear to be a practical possibility given that milk mi-
celles are remarkably tolerant to changes in composition, as
demonstrated by the knock-out of the mouse 
 
b
 
-casein gene
(29). Ethical concerns regarding the generation of transgenic
animals, which have been engineered specifically for pharma-
ceutical, medical, or nutritional reasons, lie outside the scope
of this overview, however it must be clearly ascertained that
expression of a transgene does not compromise the animal.
 
Xenograft organs for transplantation surgery
 
The shortage of human organs for transplantation has raised
interest in the possibility of xenotransplantation, i.e. the use of
animal organs (30). However, the major barrier to successful
xenogeneic organ transplantation is the phenomenon of com-
plement-mediated hyperacute rejection (HAR), brought
about by high levels of circulating natural antibodies that rec-
ognize carbohydrate determinants on the surface of xenoge-
neic cells. After transplantation of the donor organ, a massive
inflammatory response ensues through activation of the classi-
cal complement cascade. This leads to activation and destruc-
tion of the vascular endothelial cells and, ultimately, the donor
organ. The membrane-associated complement inhibitors, en-
dogenous to the donor organ, are species restricted and thus
confer only limited resistance. The complement cascade is reg-
ulated at specific points by proteins such as decay accelerating
factor (DAF), membrane cofactor protein, and CD59. These
regulators of complement activation are species specific. The
initial strategy used to address HAR in porcine-to-primate xe-
notransplantation was to produce transgenic pigs expressing
high levels of the human terminal complement inhibitor,
hCD59. This was shown to protect the xenogeneic cells from
human complement-mediated lysis in vitro (31). More re-
cently, organ transplantation has been achieved using donor
pigs which expressed human DAF on their endothelium (32),
or both DAF and CD59 on erythrocytes, such that the proteins
translocated to the cell membranes of endothelial cells (33).
After transplantation, the pig hearts survived in recipient ba-
boons for prolonged periods without rejection (33). Clearly,
such genetic manipulations are bringing xenotransplantation
ever closer to reality. If the isolation of suitable ES cells and
application of homologous recombination becomes a reality in
the pig, it may be possible to knockout the antigenic determi-
nants to which antispecies antibodies bind, as a further strat-
egy for eliminating HAR.
 
Summary
 
The use of nonmurine species for transgenesis will continue to
reflect the suitability of a particular species for the specific
questions being addressed, bearing in mind that a given con-
struct may react very differently from one species to another.
The application of transgenesis in the pig should produce ma-
jor advances in the fields of transfusion and transplantation
technology, while alterations in the composition of milk in a
range of domesticated animals will have major effects on the
production of pharmacologically important proteins and could
eventually lead to the development of human milk substitutes.
Despite the lack of germline transmission to date, major ef-
forts continue to be directed towards the generation and use of
ES cells from nonmurine species, using both traditional and
new technologies, and the availability of such cells is likely to
accelerate both the use of such species and the precision with
which genetic changes can be introduced.
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